ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,589.30
-1.22%
S&P ASX All Technology
2,978.80
-0.97%
Brent Oil
88.095
-0.06%
US Dollar vs AUD
1.53176
-0.08%
Bitcoin
64,068.15
-0.65%
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) News

ABUS Arbutus Biopharma Corporation

2.72
-0.02 (-0.73%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Arbutus Biopharma Corporation ABUS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.02 -0.73% 2.72 07:29:00
Open Price Low Price High Price Close Price Previous Close
2.74 2.68 2.75 2.72 2.74
more quote information »

Recent News

Date Time Source Heading
18/4/202421:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/4/202423:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/3/202423:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
06/3/202408:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202423:31EDGAR2Form 8-K - Current report
29/2/202423:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/2/202423:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
15/2/202408:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202402:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202411:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202411:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202411:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202411:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:31EDGAR2Form 8-K - Current report
08/1/202423:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
05/1/202408:09EDGAR2Form 8-K - Current report
22/11/202300:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/11/202308:02EDGAR2Form 8-K - Current report
08/11/202323:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
08/11/202308:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202323:31EDGAR2Form 8-K - Current report
07/11/202323:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07/11/202323:16EDGAR2Form 8-K - Current report
07/11/202323:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24/10/202322:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18/10/202322:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11/10/202323:06EDGAR2Form 8-K - Current report
11/10/202323:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
12/9/202307:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/9/202306:16EDGAR2Form 8-K - Current report
12/9/202306:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07/9/202321:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
04/8/202306:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/8/202306:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202321:31EDGAR2Form 8-K - Current report
03/8/202321:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
20/7/202321:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
14/7/202306:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/7/202306:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/7/202306:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202306:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/7/202306:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202306:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202321:31EDGAR2Form 8-K - Current report
12/7/202321:30GLOBEArbutus Appoints Melissa V. Rewolinski, PhD to its Board of..
11/7/202306:02EDGAR2Form 8-K - Current report
11/7/202306:01GLOBEArbutus Appoints Two New Executives
21/6/202321:30GLOBEArbutus Doses First Patient in Additional Treatment Arm of..
21/6/202316:01GLOBEArbutus Presents Preliminary AB-729 and Pegylated Interferon..
07/6/202316:01GLOBEArbutus to Present AB-729 and AB-836 Data at EASL Congress..

Your Recent History

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved